Insider Transactions in Q1 2021 at Novo Cure LTD (NVCR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
William F Doyle Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
9,259
+1.39%
|
$1,157,375
$125.25 P/Share
|
|
Mar 23
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
3,892
-9.68%
|
$544,880
$140.0 P/Share
|
|
Mar 23
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,892
+8.83%
|
$182,924
$47.04 P/Share
|
|
Mar 09
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
3,524
-3.36%
|
$461,644
$131.09 P/Share
|
|
Mar 08
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,004
-1.92%
|
$390,520
$130.81 P/Share
|
|
Mar 08
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
765
-0.84%
|
$99,450
$130.81 P/Share
|
|
Mar 08
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,404
-3.43%
|
$312,520
$130.81 P/Share
|
|
Mar 08
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
765
-2.09%
|
$99,450
$130.81 P/Share
|
|
Mar 08
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,627
-2.45%
|
$341,510
$130.81 P/Share
|
|
Mar 05
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,918
-8.07%
|
$382,258
$131.53 P/Share
|
|
Mar 05
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
4,550
-4.06%
|
$596,050
$131.53 P/Share
|
|
Mar 05
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,987
+11.1%
|
$97,909
$7.15 P/Share
|
|
Mar 04
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
910
-2.42%
|
-
|
|
Mar 04
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
567
-1.49%
|
$77,679
$137.55 P/Share
|
|
Mar 04
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
567
-0.62%
|
$77,679
$137.55 P/Share
|
|
Mar 04
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
3,084
-4.21%
|
$422,508
$137.55 P/Share
|
|
Mar 04
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,854
-2.4%
|
$527,998
$137.55 P/Share
|
|
Mar 04
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,658
-2.64%
|
$364,146
$137.55 P/Share
|
|
Mar 04
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,888
-4.96%
|
$258,656
$137.55 P/Share
|
|
Mar 03
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,174
-2.11%
|
$326,100
$150.78 P/Share
|
|
Mar 03
2021
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,475
-8.37%
|
$521,250
$150.78 P/Share
|
|
Mar 03
2021
|
Ely Benaim Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+7.72%
|
$239,775
$69.37 P/Share
|
|
Mar 02
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,342
+12.38%
|
-
|
|
Mar 02
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,355
-3.61%
|
$357,960
$152.05 P/Share
|
|
Mar 02
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,886
+9.57%
|
-
|
|
Mar 02
2021
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
912
-0.98%
|
$138,624
$152.05 P/Share
|
|
Mar 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,519
+7.23%
|
-
|
|
Mar 02
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,392
-1.59%
|
$363,584
$152.05 P/Share
|
|
Mar 02
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,886
+22.21%
|
-
|
|
Mar 02
2021
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
428
-1.55%
|
$65,056
$152.05 P/Share
|
|
Mar 02
2021
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+18.62%
|
-
|
|
Mar 02
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+19.35%
|
-
|
|
Mar 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
8,709
+8.7%
|
-
|
|
Mar 02
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
430
-0.52%
|
$65,360
$152.05 P/Share
|
|
Mar 02
2021
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Indirect |
111
+20.98%
|
-
|
|
Feb 27
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,715
+4.88%
|
$1,149,535
$149.1 P/Share
|
|
Feb 27
2021
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,465
+1.73%
|
$218,285
$149.1 P/Share
|
|
Feb 27
2021
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,465
+5.03%
|
$218,285
$149.1 P/Share
|
|
Feb 27
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,555
+7.85%
|
$827,695
$149.1 P/Share
|
|
Feb 27
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,259
+4.28%
|
$1,379,591
$149.1 P/Share
|
|
Feb 27
2021
|
Pritesh Shah Chief Growth Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,086
+3.22%
|
$459,814
$149.1 P/Share
|
|
Feb 22
2021
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
6,500
-19.06%
|
$1,137,500
$175.5 P/Share
|
|
Feb 22
2021
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+16.01%
|
$45,500
$7.15 P/Share
|
|
Jan 15
2021
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
63,814
-2.94%
|
$11,039,822
$173.61 P/Share
|
|
Jan 15
2021
|
Todd Christopher Longsworth General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
36,396
+22.77%
|
$509,544
$14.37 P/Share
|
|
Jan 06
2021
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53
+0.03%
|
$2,650
$50.67 P/Share
|
|
Jan 06
2021
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93
+0.07%
|
$4,650
$50.67 P/Share
|